JAK2 and acquired von willebrand syndrome: Symptomatic children or those with additional risk factors such as presence of JAK2-V617F may benefit from therapy with low-dose ASA along with careful monitoring while keeping in mind the risk of acquired von Willebrand syndrome and potentially Reye syndrome.